Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
Koutsikos
John
J
Leondi
Anastasia
A
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012211:Rhenium / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C101598:rhenium-186 HEDP; D012211:Rhenium; C061972:samarium Sm-153 lexidronam; D012968:Etidronic Acid